Commodore Capital LP
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Commodore Capital LP reported 36 stock positions worth $1.6 billion. Its top holding was Merus (MRUS) at 10.5% of the portfolio, followed by Vera Therapeutics (VERA, 6.8%) and Xenon Pharmaceuticals (XENE, 6.6%). Compared with Q2 2024, it opened 4 new positions, sold out of 3, added to 12 and reduced 9. The biggest buy was Alkermes (ALKS, shares +111%) and the biggest sale Nuvalent Class A (NUVL, shares −37%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001831942
- Portfolio Value
- $1.6B (Q3 2024)
- SEC Filing
- 0001831942-24-000009 ↗ filed Nov 14, 2024
Holdings Value
Holdings 36 stocks · $1.6B
| MRUS Merus NV | 10.46% | 3,350,000 | $167.4M | Add +4.7% |
| VERA Vera Therapeutics Inc. | 6.84% | 2,475,000 | $109.4M | No change |
| XENE Xenon Pharmaceuticals Inc. | 6.64% | 2,700,000 | $106.3M | Reduce -2.0% |
| PCVX Vaxcyte Inc. | 6.57% | 920,000 | $105.1M | Reduce -29.5% |
| ELVN Enliven Therapeutics Inc. | 6.54% | 4,100,000 | $104.7M | Add +3.2% |
| NUVL Nuvalent Inc. Class A | 6.01% | 940,000 | $96.2M | Reduce -36.8% |
| COGT Cogent Biosciences Inc. | 5.09% | 7,539,930 | $81.4M | Reduce -22.6% |
| ALKS Alkermes PLC | 5.07% | 2,900,000 | $81.2M | Add +110.9% |
| SLNO Soleno Therapeutics Inc. | 3.98% | 1,260,000 | $63.6M | Reduce -11.6% |
| SYRE Spyre Therapeutics Inc. | 3.65% | 1,988,084 | $58.5M | No change |
| VRDN Viridian Therapeutics Inc. | 3.63% | 2,550,124 | $58.0M | Add +0.9% |
| CLDX Celldex Therapeutics Inc. | 3.44% | 1,618,937 | $55.0M | Add +13.6% |
| MIND MEDICINE MINDMED INC | 2.84% | 8,000,000 | $45.5M | Add +11.9% |
| CATX Perspective Therapeutics Inc. | 2.79% | 3,350,000 | $44.7M | Reduce -28.1% |
| NRIX Nurix Therapeutics Inc. | 2.32% | 1,650,000 | $37.1M | New |
| PHVS Pharvaris NV | 2.21% | 1,911,433 | $35.4M | Add +5.6% |
| KURA Kura Oncology Inc. | 2.20% | 1,800,000 | $35.2M | Add +13.0% |
| RYTM Rhythm Pharmaceuticals Inc. | 2.13% | 650,000 | $34.1M | Reduce -46.9% |
| ORKA Oruka Therapeutics Inc. | 2.10% | 1,369,714 | $33.6M | New |
| ARVN Arvinas Inc. | 1.85% | 1,200,000 | $29.6M | Reduce -36.3% |
| CELC Celcuity Inc. | 1.42% | 1,522,332 | $22.7M | Add +4.0% |
| CNTA Centessa Pharmaceuticals Ltd. | 1.35% | 1,350,000 | $21.6M | New |
| NKTX Nkarta Inc. | 1.32% | 4,662,073 | $21.1M | Add +12.3% |
| ORIC Oric Pharmaceuticals Inc. | 1.28% | 2,000,000 | $20.5M | No change |
| CCCC C4 Therapeutics Inc. | 1.21% | 3,410,384 | $19.4M | No change |
| THRD Third Harmonic Bio Inc. | 1.15% | 1,360,569 | $18.4M | Reduce -12.0% |
| SNDX Syndax Pharmaceuticals Inc. | 1.06% | 885,000 | $17.0M | Add +7.3% |
| APGE Apogee Therapeutics Inc. | 1.06% | 290,000 | $17.0M | No change |
| ABVX Abivax SA-ADR | 0.92% | 1,284,110 | $14.8M | No change |
| TIL Instil Bio Inc. | 0.63% | 150,929 | $10.2M | New |
| NGNE Neurogene Inc. | 0.52% | 200,000 | $8.4M | No change |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.47% | 750,000 | $7.5M | No change |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.33% | 500,000 | $5.2M | No change |
| CABA Cabaletta Bio Inc. | 0.32% | 1,100,000 | $5.2M | No change |
| VTGN Vistagen Therapeutics Inc. | 0.30% | 1,575,000 | $4.7M | No change |
| AVTX Avalo Therapeutics Inc. | 0.29% | 483,000 | $4.6M | Add +1107.5% |
Portfolio Sells Q2 2024 → Q3 2024
| NUVL Nuvalent Inc. Class A | Reduce -36.8% | 6.01% | −1.69 |
| ARVN Arvinas Inc. | Reduce -36.3% | 1.85% | −1.58 |
| IMVT Immunovant Inc. | Sold out | 0.00% | −1.35 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -46.9% | 2.13% | −1.31 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -2.0% | 6.64% | −0.69 |
| COGT Cogent Biosciences Inc. | Reduce -22.6% | 5.09% | −0.51 |
| CATX Perspective Therapeutics Inc. | Reduce -28.1% | 2.79% | −0.37 |
| AUTL Autolus Therapeutics PLC | Sold out | 0.00% | −0.28 |
| THRD Third Harmonic Bio Inc. | Reduce -12.0% | 1.15% | −0.22 |
| PCVX Vaxcyte Inc. | Reduce -29.5% | 6.57% | −0.16 |
| ARCA BIOPHARMA INC | Sold out | 0.00% | −0.11 |
| SLNO Soleno Therapeutics Inc. | Reduce -11.6% | 3.98% | +0.01 |
Portfolio Buys Q2 2024 → Q3 2024
| ALKS Alkermes PLC | Add +110.9% | 5.07% | +2.81 |
| NRIX Nurix Therapeutics Inc. | New | 2.32% | +2.32 |
| ORKA Oruka Therapeutics Inc. | New | 2.10% | +2.10 |
| VRDN Viridian Therapeutics Inc. | Add +0.9% | 3.63% | +1.38 |
| CNTA Centessa Pharmaceuticals Ltd. | New | 1.35% | +1.35 |
| TIL Instil Bio Inc. | New | 0.63% | +0.63 |
| AVTX Avalo Therapeutics Inc. | Add +1107.5% | 0.29% | +0.25 |
| ELVN Enliven Therapeutics Inc. | Add +3.2% | 6.54% | +0.21 |
| KURA Kura Oncology Inc. | Add +13.0% | 2.20% | −0.04 |
| SNDX Syndax Pharmaceuticals Inc. | Add +7.3% | 1.06% | −0.09 |
| PHVS Pharvaris NV | Add +5.6% | 2.21% | −0.11 |
| CLDX Celldex Therapeutics Inc. | Add +13.6% | 3.44% | −0.16 |
| CELC Celcuity Inc. | Add +4.0% | 1.42% | −0.22 |
| NKTX Nkarta Inc. | Add +12.3% | 1.32% | −0.36 |
| MIND MEDICINE MINDMED INC | Add +11.9% | 2.84% | −0.67 |
| MRUS Merus NV | Add +4.7% | 10.46% | −2.47 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 33 | $1.7B | RLAY, ELVN, ALKS, COGT, AMLX |
| Q1 2026 | 36 | $1.7B | RLAY, ALKS, ELVN, COGT, SYRE |
| Q4 2025 | 33 | $1.5B | RLAY, ALKS, TYRA, XENE, SYRE |
| Q3 2025 | 37 | $2.0B | MRUS, NUVL, XENE, COGT, ELVN |
| Q2 2025 | 33 | $1.4B | MRUS, NUVL, XENE, ELVN, AGIO |
| Q1 2025 | 31 | $1.4B | MRUS, NUVL, ELVN, SLNO, XENE |
| Q4 2024 | 31 | $1.4B | MRUS, PCVX, NUVL, XENE, ELVN |
| Q3 2024 | 36 | $1.6B | MRUS, VERA, XENE, PCVX, ELVN |
| Q2 2024 | 35 | $1.5B | MRUS, NUVL, XENE, PCVX, ELVN |
| Q1 2024 | 39 | $1.5B | MRUS, VERA, NUVL, XENE, SYRE |